QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress expands Medicaid mental health coverage, removing 50-year-old barrier

H.R. 6727 — Repealing the IMD Exclusion Act · Filed by Ritchie Torres (D-NY) · Introduced Dec 15, 2025 · Referred to committee

65%
Transparency
Typical bill: 82%
15/100
Hidden-provision risk
Typical bill: 15/100
Mental Health Coverage Expansion

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill removes a decades-old federal restriction that bars Medicaid from paying for mental health and substance-use treatment in standalone psychiatric hospitals and facilities (called 'institutions for mental diseases' or IMDs) for patients under 65. Currently, Medicaid covers such care only for seniors; this bill extends that coverage to younger adults, provided the facilities meet federally approved standards for mental health and addiction treatment. The change takes effect 180 days after enactment.

Why we flagged it

The bill's core function is to expand Medicaid eligibility for psychiatric inpatient care by removing an age-based exclusion. It is a public-health measure that increases access to a covered benefit, not a deregulation, subsidy, or carve-out.

What the text implies

  • Removal of the IMD exclusion may increase Medicaid spending significantly, depending on state uptake and utilization rates; the bill does not cap enrollment or impose per-patient limits, leaving cost exposure open.
  • The bill delegates standard-setting to the Secretary of Health and Human Services, creating regulatory discretion over what facilities qualify; standards are not defined in statute, potentially allowing future administrations to narrow or broaden eligibility through rulemaking.

The full analysis lists 4 implications of this text.

Who stands to gain

psychiatric hospitals and inpatient mental health facilities (private and nonprofit); substance-use disorder treatment centers; pharmaceutical companies (increased treatment volume may increase medication use)

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record